JPS6153271A - ローダニン誘導体 - Google Patents

ローダニン誘導体

Info

Publication number
JPS6153271A
JPS6153271A JP59177210A JP17721084A JPS6153271A JP S6153271 A JPS6153271 A JP S6153271A JP 59177210 A JP59177210 A JP 59177210A JP 17721084 A JP17721084 A JP 17721084A JP S6153271 A JPS6153271 A JP S6153271A
Authority
JP
Japan
Prior art keywords
group
ring
lower alkyl
rhodanine
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP59177210A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0534354B2 (https=
Inventor
Michiko Nagahara
永原　美知子
Yoshitaka Oishi
義孝 大石
Motoyuki Yajima
矢嶋　基之
Katsumi Nogimori
野木森　克己
Shigeki Kurokawa
黒川　茂樹
Norio Kajikawa
梶川　憲雄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaken Pharmaceutical Co Ltd
Original Assignee
Kaken Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharmaceutical Co Ltd filed Critical Kaken Pharmaceutical Co Ltd
Priority to JP59177210A priority Critical patent/JPS6153271A/ja
Priority to CA000468545A priority patent/CA1241327A/en
Priority to ES537999A priority patent/ES537999A0/es
Priority to EP19840114373 priority patent/EP0143461B1/en
Priority to DE8484114373T priority patent/DE3479656D1/de
Priority to US06/675,580 priority patent/US4606860A/en
Publication of JPS6153271A publication Critical patent/JPS6153271A/ja
Publication of JPH0534354B2 publication Critical patent/JPH0534354B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP59177210A 1983-11-29 1984-08-24 ローダニン誘導体 Granted JPS6153271A (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP59177210A JPS6153271A (ja) 1984-08-24 1984-08-24 ローダニン誘導体
CA000468545A CA1241327A (en) 1984-08-24 1984-11-23 Rhodanine derivative, process for preparing the same and pharmaceutical composition containing the same
ES537999A ES537999A0 (es) 1983-11-29 1984-11-27 Un procedimiento para preparar un derivado de rodanina
EP19840114373 EP0143461B1 (en) 1983-11-29 1984-11-28 Rhodanine derivative, process for preparing the same and pharmaceutical composition containing the same
DE8484114373T DE3479656D1 (en) 1983-11-29 1984-11-28 Rhodanine derivative, process for preparing the same and pharmaceutical composition containing the same
US06/675,580 US4606860A (en) 1984-08-24 1984-11-28 Rhodanines useful as a therapeutic agent for diabetic complications

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59177210A JPS6153271A (ja) 1984-08-24 1984-08-24 ローダニン誘導体

Publications (2)

Publication Number Publication Date
JPS6153271A true JPS6153271A (ja) 1986-03-17
JPH0534354B2 JPH0534354B2 (https=) 1993-05-21

Family

ID=16027091

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59177210A Granted JPS6153271A (ja) 1983-11-29 1984-08-24 ローダニン誘導体

Country Status (3)

Country Link
US (1) US4606860A (https=)
JP (1) JPS6153271A (https=)
CA (1) CA1241327A (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5740478A (en) * 1980-08-22 1982-03-06 Ono Pharmaceut Co Ltd Rhodanine derivative, its preparation and aldose reductase inhibitor containing rhodanine derivative

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU334806A1 (ru) * 1969-05-28 1976-01-15 Ленинградский Технологический Институт Им.Ленсовета Способ получени 3-оксиметилроданинов
JPS5728074A (en) * 1980-07-28 1982-02-15 Ono Pharmaceut Co Ltd Rhodanine derivative, its preparation, and inhibitor for aldose reducing enzyme consisting essentially of it

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5740478A (en) * 1980-08-22 1982-03-06 Ono Pharmaceut Co Ltd Rhodanine derivative, its preparation and aldose reductase inhibitor containing rhodanine derivative

Also Published As

Publication number Publication date
US4606860A (en) 1986-08-19
JPH0534354B2 (https=) 1993-05-21
CA1241327A (en) 1988-08-30

Similar Documents

Publication Publication Date Title
JP6267397B1 (ja) 置換された多環性ピリドン誘導体およびそのプロドラッグを含有する医薬組成物
FI66383B (fi) Foerfarande foer framstaellning av farmakologiskt aktiva xantinderivat
DK2691394T3 (en) RELATIONSHIPS FOR TREATMENT OF METABOLIC SYNDROME
JPS63132889A (ja) キナゾリノン誘導体
JPS62155269A (ja) ベンゾフラン誘導体
JPS6230780A (ja) １，７−ナフチリジン誘導体及びこれを含有する薬剤
NO160995B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive bis -(4-aminofenyl)-sulfoner.
PT1142885E (pt) Derivados de 2-(n-cianoimino)tiazolidin-4-ona
CA2735417A1 (en) Glucocorticoid receptor agonist comprising novel 1,2,3,4-tetrahydroquinoxaline derivatives containing phenyl group having sulfonic acid ester structure introduced therein as substituent
JPH01294670A (ja) ２−（ピペラジニル）−２−オキソエチレン−置換フラボノイド誘導体、その製法およびそれを含有する医薬組成物
EP0143461B1 (en) Rhodanine derivative, process for preparing the same and pharmaceutical composition containing the same
JPS6153271A (ja) ローダニン誘導体
PL144481B1 (en) Process for preparing derivatives of pyrimidinotrione
US20090036437A1 (en) Pharmaceutical composition comprising phenoxazinium compound as an active ingredient
JPH03275681A (ja) ３―フェニルクマリン―７―イルオキシ酢酸誘導体とその製法及び用途
JPH01216980A (ja) アルキル―ピペラジニル―５，６―アルキレンピリミジン類
US4609736A (en) Rhodanines useful as a therapeutic agent for diabetic complications
JP2603488B2 (ja) 新規なエラグ酸硫酸エステル誘導体，その製法及び用途
WO2023072969A1 (en) Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
JPH049375A (ja) チオ尿素誘導体及びａｇｅ生成阻害剤
WO2023072961A1 (en) Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
JPS6163682A (ja) 新規テトラヒドロ‐β‐カルボリン誘導体及びその製法
JPH0558434B2 (https=)
CN121021474A (zh) 一种一氧化氮供体型化合物及其应用
JPH0827121A (ja) 新規なウラシル誘導体及びそれを有効成分とするアレルギ−疾患治療薬